Parnell Pharmaceuticals Holdings Ltd Announces Fiscal Year 2014 Financial Results OVERLAND PARK, Kan., Sept. 15, 2014 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and...

Parnell to Report Fiscal Year 2014 Financial Results September 15, 2014 OVERLAND PARK, Kan., Sept. 10, 2014 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd. (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and...

Parnell Appoints US-Based Independent Directors Phyllis Gardner, M.D., and David L. Greenwood to Its Board of Directors OVERLAND PARK, Kan., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN) today announced that it had appointed U.S. based Phyllis Gardner, MD, and David L. Greenwood...

Parnell Announces Results From the Successful Efficacy Study for Zydax(R) OVERLAND PARK, Kan., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN) today announced the results from a successful, large-scale efficacy study of Zydax, for the...